Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
94891 trials found · Page 144 of 4745
-
New hope for delaying type 1 diabetes: testing a shorter treatment option
Disease control Not yet recruitingThis is a 2-arm, multi-center, open label study to learn if ATG works the same or better than teplizumab in delaying or preventing Stage 3 Type 1 diabetes. Participants will be administered either 2 infusions of ATG or 14 infusions of teplizumab and will be followed for 12 months…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Could breast cancer treatment skip surgery? new trial explores non-surgical path
Disease control Not yet recruitingThis study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Magic mushroom compound may lift depression in lung cancer patients
Symptom relief Recruiting nowThis phase II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of major depressive disorder in patients with non-small cell lung cancer. A cancer diagnosis is life-changing, resulting in significant levels of psychological sympto…
Phase: PHASE2 • Sponsor: Alan Davis • Aim: Symptom relief
Last updated May 01, 2026 15:58 UTC
-
New vaccine-chemo combo takes on hard-to-treat neuroendocrine cancers
Disease control Recruiting nowThis phase IIa trial compares the safety and effect of temozolomide combined with survivin long peptide vaccine (SurVaxM) to temozolomide alone in patients with neuroendocrine tumors (NET) that has spread from where it first started (primary site) to other places in the body (met…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for myeloma: less frequent dosing may reduce side effects
Disease control Recruiting nowThis study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment. The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) w…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug aims to stop throat cancer from coming back
Disease control Not yet recruitingThis is a phase 2, multicentre, open-label, randomised, controlled trial with a parallel-group design. The study aims to compare the efficacy and safety of Becotatug Vedotin and capecitabine as an adjuvant therapy in patients with high-risk locoregionally advanced nasopharyngeal …
Phase: PHASE2 • Sponsor: Kai Hu • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
New Drug-Free therapy may ease dangerous pregnancy complication
Symptom relief Recruiting nowPreeclampsia is one of the most common and serious complications of pregnancy, affecting both the mother and baby. It is a condition characterized by high blood pressure and can lead to severe complications, including neurological issues and reduced blood flow to the placenta. Pr…
Phase: NA • Sponsor: Fundación Internacional René Mey • Aim: Symptom relief
Last updated May 07, 2026 18:40 UTC
-
Can a phone app speed up opioid addiction treatment? new study aims to find out
Disease control Not yet recruitingThis trial will assess effects of enrollment in a comprehensive telehealth platform, RecoveryPad (RP), in adults with moderate or severe opioid use disorder.
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
New drug combo aims to boost stem cell transplant success in hard-to-treat lymphoma
Disease control Recruiting nowThis phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to other treatments (salvage therapy) before autologous stem cell transplant in treating patients with d…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 01, 2026 15:59 UTC
-
New antibody therapy could boost transplant success in tough lymphoma
Disease control Not yet recruitingThis is an investigator-initiated, open-label, single-arm, multicenter, Phase II clinical study. The study is designed to evaluate the safety and potential effectiveness of glofitamab in adults with their disease, diffuse large B-cell lymphoma (DLBCL has either not responded to i…
Phase: PHASE2 • Sponsor: American University of Beirut Medical Center • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New hope for lymphoma patients after CAR t fails: glofitamab trial launches
Disease control Not yet recruitingThis is a Phase 2, multicentre, single arm study that evaluates the efficacy and safety of glofitamab in MCL patients with inadequate response or relapse following CAR T-cell therapy.
Phase: PHASE2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
Growing heart valve could spare kids repeated surgeries
Disease control Not yet recruitingProspective, single-arm, multi-center, continued access study of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects…
Phase: NA • Sponsor: Autus Valve Technologies, Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:39 UTC
-
New combo therapy aims to beat lymphoma without chemo
Disease control Recruiting nowThis is a phase 1/2 open-label study to evaluate GW5282 in combination with golidocitinib (G2 regimen) for the treatment of T-cell lymphoma. In the first phase of the study, the maximum tolerated dose will be determined through dose escalation; in the second phase, the potential …
Phase: PHASE1, PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New eye drug aims to outperform standard treatment for blinding disease
Disease control Recruiting nowResearchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called M…
Phase: PHASE2, PHASE3 • Sponsor: EyeBiotech Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Could a common gout pill save limbs? new trial aims to find out
Disease control Not yet recruitingChronic limb-threatening ischemia (CLTI) is the most severe form of peripheral artery disease, a condition in which narrowed or blocked arteries reduce blood flow to the legs. People with CLTI may have severe leg pain at rest, non-healing wounds, or gangrene, and face a high risk…
Phase: PHASE3 • Sponsor: Shin Kong Wu Ho-Su Memorial Hospital • Aim: Disease control
Last updated May 11, 2026 20:53 UTC
-
New hope for Drug-Resistant ovarian cancer? phase 3 trial launches
Disease control Not yet recruitingThis is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.
Phase: PHASE3 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New imaging technique could help match cancer patients to targeted treatments
Diagnosis Not yet recruitingThe purpose of this study is to use Claudin 18.2 (CLDN18.2)-targeted positron emission tomography (PET) imaging technology to evaluate its detection efficacy and diagnostic threshold for CLDN18.2-positive pancreatic cancer and gastric/gastroesophageal junction cancer, analyze the…
Sponsor: Ruijin Hospital • Aim: Diagnosis
Last updated May 11, 2026 20:53 UTC
-
New heart preservation method could save more lives
Disease control Recruiting nowHOPE for All is a clinical investigation to support the use of hypothermic oxygenated perfusion (HOPE) using a revised XVIVO Heart Assist Transport System in a real- world setting. The trial will investigate the application of HOPE in a broad population of Donation after Brain D…
Phase: NA • Sponsor: XVIVO Perfusion • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Balloon breakthrough: new device could prevent strokes in High-Risk patients
Disease control Not yet recruitingTo evaluate the safety and efficacy of the Medeliver® Intracranial Drug-Coated Balloon Catheter (developed by Beijing Jiu Shi Shen Kang Medical Technology Co., Ltd.) in the endovascular treatment of symptomatic intracranial atherosclerotic stenosis.
Phase: NA • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Tooth stem cells could regrow gum and bone without surgery
Disease control Not yet recruitingThe overall objective of this study is to evaluate the safety and efficacy of allogeneic human dental pulp stem cells (DPSCs) injected for the treatment of chronic periodontitis in humans. It aims to develop a stem cell injection therapy that promotes the regeneration of periodon…
Phase: NA • Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Disease control
Last updated May 13, 2026 16:01 UTC